TP53 and cancer: The current studies show that MLN4924 can be used in a p53 based cyclotherapy protocol, which could help reducing MLN4924 cytoxicity in healthy cells while preserving and possibly augmenting MLN4924 anti-tumour activity in cancer cells with mutant or no p53.